AMRA joins clinical trial on muscular dystrophy

By staff writers

October 15, 2021 -- AMRA Medical will be involved in the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (CTRN) to support the Motor Outcomes to Validate Evaluations Plus (MOVE+) study, a natural history study for people living with FSHD.

AMRA's whole-body MRI analysis software will be used in the study to develop biomarkers to better understand disease progression. This involves measuring 36 muscles throughout the participant's shoulders, arms, torso, and legs

The study will enroll 200 participants across 12 sites in the U.S. and two planned sites in Canada with the goal of better understanding how to utilize whole-body MRI to discover and validate specific biomarkers for FSHD that can inform future clinical trials.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking